|
NTLA | Intellia Therapeutics, Inc. |
|
|
NTLA | Intellia Therapeutics, Inc. |
| In Vitro & In Vivo Diagnostic Substances |
| Book value per $ invested | $ 0.86 |
| Leverage | 19.11% |
| Market Cap | $ 866.9m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -444.8m |
| Margin | -493.30% |
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.